In-situ Cytokines Expression in the CNS in Amyotrophic Lateral Sclerosis (ALS)

In-situ Cytokines Expression in the CNS in Amyotrophic Lateral Sclerosis

The investigators aim at exploring the differential/topographical in-situ expression of cytokines in the central nervous system (CNS) of patients who died with amyotrophic lateral sclerosis (ALS), using archived histopathology slides and residual paraffin blocks from autopsied cases. Previous studies from the investigators and other groups showed that inflammatory cytokines are implicated in several neurological affections, particularly neurodegenerative conditions. However, in-situ cytokine expression has never been studied so far in ALS. The investigators wanted to see if these neuro-mediators are involved in the neuromolecular chain/cascade underlying ALS.

Study Overview

• Status: Completed
• Conditions: Amyotrophic Lateral Sclerosis
• Intervention / Treatment: Other: in-situ cytokine expression

• Study Type: Observational
• Enrollment (Actual): 5

Contacts and Locations

Study Locations

• Belgium
  • Brussels, Belgium, 1020
    • CHU Brugmann

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: ADULT; OLDER_ADULT; CHILD
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Archived/residual histopathology slides and paraffin blocks from residual autopsy material from patients who died with amyotrophic lateral sclerosis.

Description

Inclusion Criteria:

• patients who died with amyotrophic lateral sclerosis, having been autopsied.

Exclusion Criteria:

• N/A

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Amyotrophic lateral sclerosis (ALS); Archived/residual histopathology sections and paraffin blocks, retrieved entirely from residual autopsy material from patients who died with an amyotrophic lateral sclerosis.	Other: in-situ cytokine expression
Control; Archived/residual histopathology sections and paraffin blocks, retrieved entirely from residual autopsy material from one non-ALS case.	Other: in-situ cytokine expression

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
in situ cytokine detection: interleukin 18	IHC detection on histopathology sections of paraffin embedded brain tissue.	retrospective study performed on archived paraffin blocks, autopsies performed between 2000 and 2005
in situ cytokine detection: interleukin 1	IHC detection on histopathology sections of paraffin embedded brain tissue.	retrospective study performed on archived paraffin blocks, autopsies performed between 2000 and 2005
in situ cytokine detection: interleukin 6	IHC detection on histopathology sections of paraffin embedded brain tissue.	retrospective study performed on archived paraffin blocks, autopsies performed between 2000 and 2005
in situ cytokine detection:TNF-a	IHC detection on histopathology sections of paraffin embedded brain tissue.	retrospective study performed on archived paraffin blocks, autopsies performed between 2000 and 2005

Collaborators and Investigators

• Sponsor: Brugmann University Hospital
• Investigators: Principal Investigator: Hazim Kadhim, MD, PhD, CHU Brugmann

Study record dates

Study Major Dates

• Study Start: October 1, 2012
• Primary Completion (Actual): February 1, 2015
• Study Completion (Actual): February 1, 2015

Study Registration Dates

• First Submitted: October 20, 2015
• First Submitted That Met QC Criteria: October 20, 2015
• First Posted (Estimate): October 21, 2015

Study Record Updates

• Last Update Posted (Estimate): October 21, 2015
• Last Update Submitted That Met QC Criteria: October 20, 2015
• Last Verified: October 1, 2015

More Information

Terms related to this study

• Keywords: Cytokines; Amyotrophic lateral sclerosis (ALS); Neuropathology
• Additional Relevant MeSH Terms: Pathologic Processes; Metabolic Diseases; Central Nervous System Diseases; Nervous System Diseases; Neuromuscular Diseases; Neurodegenerative Diseases; Spinal Cord Diseases; TDP-43 Proteinopathies; Proteostasis Deficiencies; Sclerosis; Motor Neuron Disease; Amyotrophic Lateral Sclerosis
• Other Study ID Numbers: CHUB-ALS